Physician profile
Sharon Hoopingarner
NPI 1093747784
$2,812.69
in general payments reported to CMS, 2019-2025
19 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $136 · 2023: $315 · 2024: $493 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.80 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.61 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $486.71 | 2021-2025 | Caplyta |
| Alkermes, INC. | $425.06 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $262.80 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $218.67 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $171.09 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $151.74 | 2021-2025 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $109.75 | 2022-2025 | Invega, Spravato |
| Lundbeck LLC | $80.93 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $70.24 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $54.56 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $49.08 | 2021-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $48.91 | 2022-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $39.36 | 2021 | |
| Noven Therapeutics, LLC | $33.00 | 2021-2024 | Secuado |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.53 | 2025 | Trintellix |
| Sage Therapeutics, LLC | $17.06 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $15.48 | 2022 | |
| Corium, LLC | $4.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Hoopingarner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.